FI962990A - Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä - Google Patents
Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä Download PDFInfo
- Publication number
- FI962990A FI962990A FI962990A FI962990A FI962990A FI 962990 A FI962990 A FI 962990A FI 962990 A FI962990 A FI 962990A FI 962990 A FI962990 A FI 962990A FI 962990 A FI962990 A FI 962990A
- Authority
- FI
- Finland
- Prior art keywords
- aav
- pct
- associated viruses
- recombinant adeno
- producing recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9400934A FR2716682B1 (fr) | 1994-01-28 | 1994-01-28 | Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations. |
PCT/FR1995/000054 WO1995020671A1 (fr) | 1994-01-28 | 1995-01-18 | Procede de preparation de virus adeno-associes (aav) recombinants et utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
FI962990A true FI962990A (fi) | 1996-07-26 |
FI962990A0 FI962990A0 (fi) | 1996-07-26 |
Family
ID=9459501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI962990A FI962990A0 (fi) | 1994-01-28 | 1996-07-26 | Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä |
Country Status (17)
Country | Link |
---|---|
US (1) | US5789390A (fi) |
EP (1) | EP0741793B1 (fi) |
JP (1) | JP3810078B2 (fi) |
KR (1) | KR100403708B1 (fi) |
AT (1) | ATE310097T1 (fi) |
AU (1) | AU706647B2 (fi) |
CA (1) | CA2181602A1 (fi) |
DE (1) | DE69534618T2 (fi) |
DK (1) | DK0741793T3 (fi) |
ES (1) | ES2252738T3 (fi) |
FI (1) | FI962990A0 (fi) |
FR (1) | FR2716682B1 (fi) |
IL (1) | IL112461A0 (fi) |
MX (1) | MX9603002A (fi) |
NO (1) | NO319885B1 (fi) |
WO (1) | WO1995020671A1 (fi) |
ZA (1) | ZA95628B (fi) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6814962B1 (en) * | 1994-06-02 | 2004-11-09 | Aventis Pharma S.A. | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same |
US5658785A (en) * | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) * | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
IL116816A (en) * | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
FR2738575B1 (fr) * | 1995-09-08 | 1997-10-10 | Centre Nat Rech Scient | Cellules pour la production d'adenovirus recombinants |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
US5756283A (en) * | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
US6207457B1 (en) * | 1995-09-08 | 2001-03-27 | Avigen, Inc. | Targeted nucleotide sequence delivery and integration system |
US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
US20030027250A1 (en) * | 1995-12-15 | 2003-02-06 | Mitchell Lloyd G. | Methods and compositions for use in spliceosome mediated RNA trans-splicing |
US20060088938A1 (en) * | 1995-12-15 | 2006-04-27 | Mitchell Lloyd G | Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants |
US5846528A (en) | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5858351A (en) | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
US20020037867A1 (en) * | 1999-02-26 | 2002-03-28 | James M. Wilson | Method for recombinant adeno-associated virus-directed gene therapy |
KR20000048623A (ko) * | 1996-09-25 | 2000-07-25 | 쎌 제네시스, 인코퍼레이티드 | 아데노-수반 바이러스 벡터의 비침습성 투여방법 |
EP0950091A2 (en) * | 1996-12-18 | 1999-10-20 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
US20040161409A1 (en) * | 1997-07-25 | 2004-08-19 | Kurtzman Gary J. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
US6242426B1 (en) * | 1997-07-25 | 2001-06-05 | Avigen, Inc. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
US6348450B1 (en) * | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
US20030045492A1 (en) * | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
US20030125278A1 (en) * | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
US6251677B1 (en) | 1997-08-25 | 2001-06-26 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
BR9813391C1 (pt) * | 1997-12-03 | 2021-05-25 | Roche Diagnostics Gmbh | processo para produzir uma composição de epo e processo para aumentar a atividade específica de uma composição de epo |
DE19830141A1 (de) * | 1998-07-06 | 2000-01-13 | Regine Heilbronn | Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren |
US6303362B1 (en) | 1998-11-19 | 2001-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adenoviral vector and methods for making and using the same |
US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
US6387368B1 (en) | 1999-02-08 | 2002-05-14 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV virus and methods of use thereof |
DE19905501B4 (de) * | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
US20040043488A1 (en) * | 1999-02-17 | 2004-03-04 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Adeno-associated viral gene-transfer vector system |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
US7208315B2 (en) | 2000-01-05 | 2007-04-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for efficient AAV vector production |
EP1259626B1 (en) * | 2000-02-25 | 2007-10-31 | Ludwig Institute For Cancer Research | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins and screening methods for modulators |
US20050124010A1 (en) * | 2000-09-30 | 2005-06-09 | Short Jay M. | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating |
US6916635B2 (en) * | 2000-10-02 | 2005-07-12 | The Research Foundation Of State University Of New York | Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof |
US20040126774A1 (en) * | 2001-01-08 | 2004-07-01 | Mitchell Lioyd G. | Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing |
EP1381276A4 (en) | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION |
US6838285B2 (en) | 2001-09-18 | 2005-01-04 | Becton Dickinson | Site specific recombinase based method for producing adenoviral vectors |
US7399753B2 (en) * | 2002-02-25 | 2008-07-15 | Virxsys Corporation | Trans-splicing mediated photodynamic therapy |
JP2005536231A (ja) * | 2002-05-08 | 2005-12-02 | イントロン,インコーポレーテッド | アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用 |
EP1579004B1 (en) * | 2002-10-23 | 2010-06-16 | VIRxSYS Corporation | Screening methods for identification of efficient pre-trans-splicing molecules |
WO2005025517A2 (en) * | 2003-09-12 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Animal model for protease activity and liver damage |
WO2005070023A2 (en) * | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Expression of apoa-1 and variants thereof using spliceosome mediated rna trans-splicing |
WO2005070948A1 (en) * | 2004-01-23 | 2005-08-04 | Intronn, Inc. | Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated rna trans splicing |
US7968334B2 (en) * | 2004-01-23 | 2011-06-28 | Virxsys Corporation | Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing |
JP2007522814A (ja) * | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | ウイルスの精製方法 |
EP1732947B1 (en) * | 2004-03-05 | 2011-04-27 | Vegenics Pty Ltd | Growth factor binding constructs materials and methods |
US7319015B2 (en) * | 2004-03-16 | 2008-01-15 | The Regents Of The University Of Michigan | Methods and compositions for using alveolar macrophage phospholipase A2 |
US7582442B2 (en) | 2004-03-16 | 2009-09-01 | The Regents Of The University Of Michigan | Methods and compositions for using aleveolar macrophage phospholipase A2 |
EP1755400A2 (en) * | 2004-06-18 | 2007-02-28 | The University Of Montana | Aav mediated gene delivery to cochlear cells |
US20090233986A1 (en) * | 2004-07-27 | 2009-09-17 | Mount Sinai School Of Medicine | Methods and compositions for using sax2 |
US20060094110A1 (en) * | 2004-07-30 | 2006-05-04 | Mcgarrity Gerard J | Use of spliceosome mediated RNA trans-splicing for immunotherapy |
US20060134658A1 (en) * | 2004-08-09 | 2006-06-22 | Garcia-Blanco Mariano A | Use of RNA trans-splicing for generation of interfering RNA molecules |
FI20050753A (fi) | 2004-09-03 | 2006-03-04 | Licentia Oy | Uudet peptidit |
DE102004047492B4 (de) * | 2004-09-23 | 2006-07-20 | Jost-Werke Gmbh & Co. Kg | Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem |
CA2583306A1 (en) * | 2004-10-08 | 2006-08-10 | Intronn, Inc. | Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production |
US7871795B2 (en) | 2004-10-08 | 2011-01-18 | Virxsys Corporation | Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins |
US7531523B2 (en) | 2005-02-17 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Sodium channel protein type III alpha-subunit splice variant |
EP1863511A2 (en) * | 2005-02-23 | 2007-12-12 | UAB Research Foundation | Alkyl-glycoside enhanced vaccination |
WO2006108707A1 (en) * | 2005-04-11 | 2006-10-19 | Crucell Holland B.V. | Virus purification using ultrafiltration |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
US20080200408A1 (en) * | 2005-09-30 | 2008-08-21 | Mccormack Kenneth | Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit |
US7972813B2 (en) * | 2005-09-30 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Tetrodotoxin-resistant sodium channel alpha subunit |
ATE480559T1 (de) | 2005-12-14 | 2010-09-15 | Licentia Ltd | Verwendungen eines neurotrophischen faktors |
US20090214496A1 (en) * | 2006-01-30 | 2009-08-27 | Licentia Ltd. | Bmx/etk tyrosine kinase gene therapy materials and methods |
DK2548579T3 (en) | 2006-05-17 | 2015-11-30 | Ludwig Inst Cancer Res | TARGET OBJECTIVE OF VEGF-B REGULATION OF FATTY ACID TRANSPORTERS FOR MODULATING HUMAN DISEASES |
FI20070808A0 (fi) | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
US20090196854A1 (en) * | 2008-02-04 | 2009-08-06 | Kytos Biosystems S.A. | Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery |
FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
EP2318036B1 (en) | 2008-06-30 | 2015-06-03 | The Regents of the University of Michigan | Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis |
AU2012255143A1 (en) | 2011-05-19 | 2014-02-20 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
PT2785683T (pt) | 2011-11-30 | 2020-04-16 | Ludwig Inst For Cancer Res Ltd | Moduladores de célula inkt e métodos para o seu uso |
GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
HUE039676T2 (hu) | 2012-09-06 | 2019-01-28 | Univ Chicago | Antiszensz polinukleotidok exon-ugrás indukálására és eljárások disztrófiák kezelésére |
WO2014124487A1 (en) | 2013-02-18 | 2014-08-21 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
WO2014191630A2 (en) | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
BR112017021485A2 (pt) | 2015-04-08 | 2018-07-03 | Univ Northwestern | oligonucleotídeo antissentido isolado, composição farmacêutica, métodos para induzir salto de éxon de um rna de sarcoglicano gama, para aliviar distrofia muscular de cinturas tipo 2c, para inibir a progressão de patologia distrófica associada a lgmd2c e para aprimorar função muscular, e, kit. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
-
1994
- 1994-01-28 FR FR9400934A patent/FR2716682B1/fr not_active Expired - Fee Related
-
1995
- 1995-01-18 AT AT95907045T patent/ATE310097T1/de not_active IP Right Cessation
- 1995-01-18 DK DK95907045T patent/DK0741793T3/da active
- 1995-01-18 JP JP51990995A patent/JP3810078B2/ja not_active Expired - Fee Related
- 1995-01-18 WO PCT/FR1995/000054 patent/WO1995020671A1/fr active IP Right Grant
- 1995-01-18 KR KR1019960704129A patent/KR100403708B1/ko not_active IP Right Cessation
- 1995-01-18 US US08/682,520 patent/US5789390A/en not_active Expired - Fee Related
- 1995-01-18 DE DE69534618T patent/DE69534618T2/de not_active Expired - Fee Related
- 1995-01-18 ES ES95907045T patent/ES2252738T3/es not_active Expired - Lifetime
- 1995-01-18 AU AU15395/95A patent/AU706647B2/en not_active Ceased
- 1995-01-18 EP EP95907045A patent/EP0741793B1/fr not_active Expired - Lifetime
- 1995-01-18 MX MX9603002A patent/MX9603002A/es not_active IP Right Cessation
- 1995-01-18 CA CA002181602A patent/CA2181602A1/fr not_active Abandoned
- 1995-01-26 IL IL11246195A patent/IL112461A0/xx active IP Right Grant
- 1995-01-26 ZA ZA95628A patent/ZA95628B/xx unknown
-
1996
- 1996-07-12 NO NO19962950A patent/NO319885B1/no unknown
- 1996-07-26 FI FI962990A patent/FI962990A0/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE310097T1 (de) | 2005-12-15 |
DK0741793T3 (da) | 2006-03-27 |
IL112461A0 (en) | 1995-03-30 |
EP0741793B1 (fr) | 2005-11-16 |
KR100403708B1 (ko) | 2004-05-31 |
AU706647B2 (en) | 1999-06-17 |
ZA95628B (en) | 1995-10-23 |
MX9603002A (es) | 1997-06-28 |
ES2252738T3 (es) | 2006-05-16 |
JP3810078B2 (ja) | 2006-08-16 |
NO962950L (no) | 1996-07-12 |
JPH09509051A (ja) | 1997-09-16 |
EP0741793A1 (fr) | 1996-11-13 |
WO1995020671A1 (fr) | 1995-08-03 |
US5789390A (en) | 1998-08-04 |
NO962950D0 (no) | 1996-07-12 |
NO319885B1 (no) | 2005-09-26 |
AU1539595A (en) | 1995-08-15 |
DE69534618D1 (de) | 2005-12-22 |
CA2181602A1 (fr) | 1995-08-03 |
DE69534618T2 (de) | 2006-07-27 |
FR2716682B1 (fr) | 1996-04-26 |
FI962990A0 (fi) | 1996-07-26 |
FR2716682A1 (fr) | 1995-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI962990A (fi) | Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AAV:iden) valmistamiseksi ja sen käyttöjä | |
ATE362542T1 (de) | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten | |
WO1995006743A3 (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
DE69739860D1 (de) | Rekombinante AAV zur Herstellung eines Medikaments für die Gentherapie von Muskelzellen | |
NO950939L (no) | Defektive adenovirusvektorer og deres anvendelse i gene-terapien | |
NO950534L (no) | Modufiserte soppceller og fremgangsmåter for fremstilling av rekombinante produkter | |
ATE402254T1 (de) | Aav5 vektoren und deren verwendung | |
TR199802789T2 (xx) | Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar. | |
EP0710288A4 (en) | ADENOVIRAL VECTORS FOR TREATMENT OF HEMOPHILIA | |
DE59913833D1 (de) | Strukturprotein von aav, seine herstellung und verwendung | |
CY1106216T1 (el) | 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ | |
DE69635931D1 (de) | Komplementäre adenovirenvektorsysteme und zellinien | |
DE69229476D1 (de) | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe | |
ATE328068T1 (de) | Papillomavirus vakzine | |
DE69731611D1 (de) | Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor | |
EP1005376A4 (en) | METHODS AND COMPOSITIONS FOR USE IN GENE THERAPY IN THE TREATMENT OF HEMOPHILIA | |
ATE202487T1 (de) | Mono- oder polyfunktionelle konjugate von polylysine | |
CY1105240T1 (el) | 5’ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ | |
ATE189697T1 (de) | Die hocheffiziente herstellung und isolierung von viruspartikeln | |
FI973309A (fi) | Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi | |
NZ505063A (en) | Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions | |
DE59610632D1 (de) | Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität | |
EP0770137A4 (en) | IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS | |
DK0627004T3 (da) | Forbedringer ved eller i forbindelse med malariavaccine | |
ATE435915T1 (de) | Spezifische nukleinsäuren und polypeptide aus krankheitserregenden stämmen von neisseria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |